Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASH

15 Jul 2025

Abstract excerpt

Background & Aims: Steatotic liver disease can lead to the development of metabolic dysfunction-associated steatohepatitis (MASH), the prevalence of which is rapidly increasing, intensifying the need to find an effective treatment. GTX-11 is a first-in-class drug with anti-inflammatory and antifibrotic properties mediated by the modulation of the transforming growth factor beta pathway. The present study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Liver Disease Diagnosis and Treatment
Share to Liver Diseases and Immunity
Share to Liver physiology and pathology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40980160
DOI: 10.1016/j.jhepr.2025.101497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GTX-11 improves portal hypertension, liver fibrosis, and sinusoidal cells phenotype in experimental MASHPMID 40980160Read ↗

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)Semantic proximity Read ↗

Multiomics analyses decipher intricate changes in the cellular and metabolic landscape of steatotic livers upon dietary restriction and sleeve gastrectomySemantic proximity Read ↗

Combined Semaglutide and Exercise Ameliorate HFpEF-Associated MASH: Multi-Omics InsightsSemantic proximity Read ↗

Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH.Semantic proximity Read ↗

Cilostazol Preserves Central Sinusoidal Endothelium and Attenuates Fibrosis in a Diabetic Steatohepatitis ModelSemantic proximity Read ↗

An LSEC-focused computational drug repurposing platform for liver fibrosis: Identification of vorinostat and other LSEC-protective candidatesSemantic proximity Read ↗

A Unified Mechanistic Framework for Metabolism-Based Therapeutics in MASH: A Comprehensive Review of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and StatinsSemantic proximity Read ↗

Current Insights into Liver Fibrosis: Epidemiological Patterns, Etiopathogenesis, Clinical Correlates, and Research AgendaSemantic proximity Read ↗

A new dietary rat model fully recapitulates metabolic dysfunction-associated steatotic liver disease pathophysiology and mimics human disease with advanced liver fibrosis and portal hypertensionSemantic proximity Read ↗

Rationale and targets for antifibrotic therapies.Semantic proximity Read ↗

Diet-induced MASH liver fibrosis promoted by EphB2 can be targeted by small molecule tetramerization inhibitorsSemantic proximity Read ↗

Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.